Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#assertion>. }
Showing items 1 to 11 of
11
with 100 items per page.
- association type Statement assertion.
- association label "Bromocriptine mesylate tablets are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing "end of dose failure" on levodopa therapy." assertion.
- association subject CHEBI:3182 assertion.
- association predicate treats assertion.
- association object MONDO:0001945 assertion.
- association relation SymptomaticReliefIndication assertion.
- MONDO:0001945 category Disease assertion.
- CHEBI:3182 category Drug assertion.
- association association_type ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.
- association publications drugInfo.cfm?setid=93a0696b-b261-4262-9e06-f3180b419f8f assertion.
- association provided_by "NeuroDKG" assertion.